Skip to content

Mescaline: all studies

Page 3 of 97: studies 21 to 30 of 963, newest first. Back to the mescaline overview

Research

Safety pharmacology of acute mescaline administration in healthy participants.

British Journal of Clinical Pharmacology November 25, 2024 Aaron Klaiber, Mélusine Humbert‐droz, Laura Ley et al. 6 citations

Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. The present pooled analysis included two double-blind, randomized, placebo-controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral-dose administrations (n = 16/dose) of mescaline at doses of 100-800 mg were...

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.

Translational Psychiatry September 30, 2024 Aaron Klaiber, Yasmin Schmid, Anna M Becker et al. 27 citations

Classic psychedelics have regained interest in research and therapy. Despite the long tradition of the human use of mescaline, modern data on its dose-dependent acute effects and pharmacokinetics are lacking. Additionally, its mechanism of action has not been investigated in humans. We used a randomized, double-blind, placebo-controlled, crossover design in 16 healthy subjects (8 women) who...

Behavioral pharmacology of mescaline - the role of serotonin 5-HT2A, 5-HT2B, 5-HT2C and 5-HT1A receptors

bioRxiv Preprint Server August 28, 2024 Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al. preprint

Rationale Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.

Hitting the Reset Button: Ceremonial Use of Peyote and Experiences of Personal Change

Journal of Drug Issues August 22, 2024 Heith Copes, Andrew Hochstetler, Jared Ragland et al. 3 citations

Our aim is to understand how those who use peyote in a naturalistic setting discuss it changed their lives and to what they attribute this change. To do this, we draw on data from a photo-ethnography of people who attended peyote ceremonies in rural Northcentral Alabama. Broadly, we found that participants discussed four core areas of change: reduced drug and alcohol misuse, new perspectives on...

Plant drugs: Transcending the mescaline biosynthesis.

Current Biology August 19, 2024 Vincent Courdavault, Nicolas Papon 1 citation

Our knowledge of the biosynthesis of medicinal compounds from plants remains limited. A new study has deciphered the complete metabolic pathway leading to the biosynthesis of the psychedelic mescaline in the cactus peyote, suggesting the development of biotechnological strategies for a sustainable supply of this important plant drug.

DOI: 10.1016/j.cub.2024.06.061 (opens in new tab) Full text (opens in new tab) Psychedelics Plant biochemistry Natural compounds Conservation biology +1

The biosynthetic pathway of the hallucinogen mescaline and its heterologous reconstruction

Molecular Plant June 3, 2024 Paula Berman, Luis Alejandro de Haro, Ana-Rita Cavaco et al. 15 citations

Mescaline, among the earliest identified natural hallucinogens, holds great potential in psychotherapy treatment. Nonetheless, despite the existence of a postulated biosynthetic pathway for more than half a century, the specific enzymes involved in this process are yet to be identified. In this study, we investigated the cactus Lophophora williamsii (Peyote), the largest known natural producer...

DOI: 10.1016/j.molp.2024.05.012 (opens in new tab) Mescaline Heterologous Computational biology Hallucinogen +1

Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.

Journal of Clinical Oncology June 1, 2024 Amrit Baral, Yue Pan, Alberto J. Caban Martinez et al.

e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...

Peyote Shrines, Remembrance, and Ritual Surrogacy in South Texas

Journal for the Study of Religion, Nature and Culture March 13, 2024 Servando Z. Hinojosa

Peyote grows in South Texas where licensed dealers acquire it and sell it to Native American Church members. These dealers also create and maintain special shrines on their property for the visiting buyers. The shrines not only mark a portal of entry into the region but also comprise the only opportunity many Native Americans will have to see peyote growing in the ground. Prompting prayers and...

DOI: 10.1558/jsrnc.22667 (opens in new tab) Ethnology Archaeology Ancient history Anthropology

An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture

Molecules December 5, 2023 Marjolein Doesburg-Van Kleffens, Amy Marisa Zimmermann-Klemd, Carsten Gründemann 13 citations

Peyote (Lophophora williamsii) is a cactus that contains various biologically active alkaloids—such as pellotine, anhalonidine, hordenine and mescaline. Here, mescaline induces the psychoactive effects of peyote through the activation of the serotonin 5-HT2A receptor and the subsequent release of calcium (Ca2+) from the endoplasmic reticulum (ER). Moreover, an evaluation of the therapeutic...